Tag Archives: Teva Pharmaceutical Industries Ltd

Business, Finance, Occupation & Industry

Teva to Report First Quarter 2013 Financial Results on May 2, 2013

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Teva to Report First Quarter 2013 Financial Results on May 2, 2013

JERUSALEM–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYS: TEVA) announced today that it will release its first quarter 2013 financial results on Thursday, May 2, 2013 at 7:00 a.m. ET.

Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its first quarter 2013 results and overall business environment. A Question & Answer session will follow this discussion.

In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States and Canada 1-888-771-4371; International 1-847-585-4405; passcode: 34657214.

A live webcast of the call will also be available on Teva’s website at: www.tevapharm.com. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company’s website. The replay can also be accessed until May 9, 2013, at 11:59 p.m. ET by calling 1-888-843-7419 or 1-630-652-3042; passcode: 34657214.


About Teva

Teva Pharmaceutical Industries Ltd. (NYS: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva’s branded businesses focus on CNS, oncology, pain, respiratory and women’s health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.

Teva Pharmaceutical Industries Ltd.
IR:
Kevin C. Mannix
United States
215-591-8912
or
Kristen Frank
United States
215-591-8908
or
Tomer Amitai
Israel
972 (3) 926-7656
or
PR:
Hadar Vismunski-Weinberg
Israel
972 (3) 926-7687
or
Denise Bradley
United States
215-591-8974

KEYWORDS:   Middle East  Israel

INDUSTRY KEYWORDS:

The …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Teva-Handok Names Yoo Suk Hong as Chief Executive Officer

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Teva-Handok Names Yoo Suk Hong as Chief Executive Officer

  • Yoo Suk Hong, previous Lilly Korea CEO, recruited as first CEO of Teva-Handok
  • Teva-Handok is scheduled to officially launch in September

JERUSALEM & SEOUL, South Korea–(BUSINESS WIRE)– Teva-Handok today announced the appointment of Yoo Suk Hong as the first Chief Executive Officer of the business venture established between Teva Pharmaceutical Industries Ltd. (NYS: TEVA) and Handok Pharmaceuticals (KRX: 002390). This business venture was formed in February, 2013 and focuses on the Korean pharmaceutical market, currently valued at approximately USD 14 billion.

“As we prepare to officially launch Teva-Handok, we are very pleased to welcome Yoo Suk Hong as our CEO,” stated Prof. Itzhak Krinsky, Chairman of Teva Japan, Chairman of Teva South Korea and Head of Business Development Asia Pacific. “With his deep international experience coupled with his keen understanding of the Korean market, Yoo Suk will help us realize our goal of bringing high-quality and affordable medicines to patients in Korea.”

Handok Pharmaceutical’s Chairman and CEO Young Jin Kim stated, “CEO Yoo Suk Hong has had a variety of work experiences in both Lilly headquarter and Korea with remarkable achievements. I believe with his competencies developed through global leadership, he will help establish Teva Handok as a leader in the Korean market.”

Teva-Handok is expected to officially launch its first products in September 2013.

About Yoo Suk Hong

CEO Yoo Suk Hong graduated from Hankuk University of Foreign Studies and received an MBA from the Wharton School of Business, University of Pennsylvania. He worked as a financial analyst at Eli Lilly‘s headquarters in the US starting in 1992 and returned to Korea in 1995 first in new product marketing and then as the head of marketing and sales. In 2003, Mr. Hong was appointed as the global marketing manager of an osteoporosis medication at Lilly’s US headquarters. He was appointed as the CEO of Lilly Korea in 2007 and then sent again to the headquarters in 2008 as the marketing strategy director of emerging markets covering areas such …read more

Source: FULL ARTICLE at DailyFinance

Articles of Interest

Tecfidera, Oral Multiple Sclerosis Drug, Approved By FDA

Leave a comment

By The Huffington Post News Editors

By Toni Clarke
March 27 (Reuters) – U.S. regulators have approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales of more than $3 billion.
The drug, Tecfidera, activates a chemical pathway in the body known as Nrf2 which helps protect nerve cells from damage and inflammation. It is expected to be launched within days.
Multiple sclerosis is a chronic condition which attacks the central nervous system and can lead to numbness, weakness, paralysis and blindness. It affects more than 2.1 million people worldwide, according to the National Multiple Sclerosis Society.
The U.S. Food and Drug Administration said on Wednesday that the drug may decrease a patient’s white blood cell. White blood cells help protect the body from infection, and while no significant increase in infections was seen during clinical trials of the drug, the agency recommended patients have their white blood cell count assessed before treatment and once a year after that.
Biogen already sells the MS drugs Avonex and Tysabri, which together account for about 30 percent of the market. Teva Pharmaceutical Industries Ltd’s drug Copaxone is the current market leader, with a roughly 29 percent share and annual sales last year of more than $4 billion.
Unlike Copaxone, Avonex and Tysabri, which are injected or infused, Tecfidera comes in the more convenient form of a pill. As such, it will compete with Novartis AG’s MS pill Gilenya, which, though first to market, has been dogged by heart safety concerns. Gilenya holds an 8.5 percent share of the market and generated worldwide sales of $1.2 billion last year.

Read More…
More on Video

…read more
Source: FULL ARTICLE at Huffington Post

Business, Finance, Occupation & Industry

New Data Show Azilect® (rasagiline tablets) Provided Clinical Benefit in Patients with Early Parkins

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

New Data Show Azilect ® (rasagiline tablets) Provided Clinical Benefit in Patients with Early Parkinson’s When Added to Sub-Optimally Controlled Patients on Dopamine Agonist Therapy

Results Add to Evidence for Azilect as an Effective and Well-Tolerated Treatment Option at Different Stages of the Progression of Parkinson’s Disease (PD)

JERUSALEM–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYS: TEVA) and H. Lundbeck A/S announced today that a double-blind, placebo controlled, randomized, multicenter study of Azilect® (rasagiline tablets) met its primary endpoint. The study, known as ANDANTE (Add oN to Dopamine AgoNists in the TrEatment of Parkinson’s disease), assessed the efficacy and tolerability of Azilect as add-on treatment to dopamine agonists compared to placebo. While the efficacy of Azilect as adjunct to levodopa has been established in previous studies (leading to its indication as adjunct therapy to levodopa), its efficacy in combination with dopamine agonist monotherapy has not previously been studied.

Results from the study demonstrated that the addition of Azilect 1mg/day provided a statistically significant improvement (Primary endpoint: treatment effect ± SE -2.4 ± 0.95 [95% CI -4.3,-0.5, p=0.012]) in total Unified Parkinson’s Disease Rating Scale (UPDRS) score (Parts I, II and III, version three) from baseline to week 18 in patients sub-optimally controlled with dopamine agonist monotherapy compared to placebo. Azilect was well-tolerated with no significant difference in adverse events compared to placebo.

“The positive outcome of this study is important news for the PD community, for patients and physicians,” said Robert A. Hauser, M.D., M.B.A., Director, Parkinson’s Disease & Movement Disorders Center at the University of South Florida and primary investigator of the study. “In addition to rasagiline providing symptomatic benefit to patients sub-optimally controlled with dopamine agonist monotherapy, the study confirmed that rasagiline is well-tolerated and provided proof-of-concept for adding rasagiline to dopamine agonist therapy.”

As a monoamine oxidase B (MAO-B) inhibitor, Azilect acts by increasing available synaptic dopamine. This mode of action provided the rationale for add-on therapy to dopamine agonists in the management of PD.

“The ANDANTE data continue to clarify the clinical profile of Azilect and the role it plays in helping to meet the needs of those living with PD, at multiple points in the progression of their disease,” said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries Ltd. “Teva is committed to the continued research and understanding of Azilect in PD and to sharing important findings like these with the scientific community.”

…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Teva to Present New Research on CNS Product Portfolio and Pipeline at 2013 American Academy of Neuro

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Teva to Present New Research on CNS Product Portfolio and Pipeline at 2013 American Academy of Neurology Annual Meeting

LATE-BREAKING ORAL PRESENTATION PLANNED FOR AZILECT ® (RASAGILINE TABLETS)

JERUSALEM–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYS: TEVA) today announced that 15 abstracts highlighting study results for Parkinson’s disease (PD) and relapsing-remitting multiple sclerosis (RRMS) will be presented during the 65th American Academy of Neurology (AAN) annual meeting in San Diego, Calif., March 16-23, 2013. New data for AZILECT® (rasagiline tablets), an MAO-B inhibitor for the treatment of PD, will be presented as part of the meeting’s Emerging Science program (formerly known as Late-Breaking Science) on Wednesday, March 20th at 5:45pm PST.

“We are pleased with the variety of topics and quality of research results that will be presented at AAN this year,” said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries Ltd. “Teva’s legacy in CNS is grounded in our commitment to ongoing collaboration with academia, medical institutions, and patient advocacy groups to find innovative solutions for patients who live with chronic and debilitating diseases, such as RRMS and Parkinson’s disease.”

Featured presentations include:

  • Results from a Phase IV clinical study evaluating AZILECT® as Add on to Dopamine Agonists in the Treatment of Parkinson’s disease (ANDANTE).
  • Findings from the first year of follow-up in the Therapy Optimization in Multiple Sclerosis (TOP MS) study, the largest prospective Phase IV study conducted in RRMS, providing insight into the impact of adherence to therapy, as well as data demonstrating that more patients on COPAXONE® (glatiramer acetate) persisted with treatment than those on beta interferon (IFN).
  • Results from the Phase III ALLEGRO study in RRMS at 36 months, comparing the progression of disability and safety of patients treated with laquinimod for three years (Early-Start) and in patients originally treated with placebo in the double-blind (DB) phase and switched to laquinimod treatment (Delayed-Start) in the open-label (OL) phase of the ALLEGRO trial.

Platform Presentation/Poster Session Details:


AZILECT
 ®

Business, Finance, Occupation & Industry

Teva to Present at the 2013 Barclays Global Healthcare Conference

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Teva to Present at the 2013 Barclays Global Healthcare Conference

JERUSALEM–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYS: TEVA) will host a live audio webcast at the 2013 Barclays Global Healthcare Conference. Eyal Desheh, Chief Financial Officer, Teva Pharmaceutical Industries Ltd. will present on Thursday, March 14, 2013.

…read more
Source: FULL ARTICLE at DailyFinance

     
What: Teva Presentation at the Barclays Global Healthcare Conference
 
Who: Eyal Desheh, Chief Financial Officer, Teva Pharmaceutical Industries Ltd.
Business, Finance, Occupation & Industry

Teva Files 2012 Annual Report on Form 20-F

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Teva Files 2012 Annual Report on Form 20-F

JERUSALEM–(BUSINESS WIRE)– In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd. (NYS: TEVA) announced today that it has filed its 2012 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company’s website at www.tevapharm.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company’s complete audited financial statements, free of charge. Requests can be made by contacting Teva Investor Relations at 1090 Horsham Road, North Wales PA, 19454 or by phone at (215) 591-8912 or 011-972-3-926-7656.

About Teva

Teva Pharmaceutical Industries Ltd. (NYS: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva’s branded businesses focus on CNS, oncology, pain, respiratory and women’s health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.

Teva Pharmaceutical Industries Ltd.
IR:
United States
Kevin C. Mannix, 215-591-8912
Kristen Frank, 215-591-8908
or
Israel
Tomer Amitai, 972 (3) 926-7656
or
PR:
Israel
Hadar Vismunski-Weinberg, 972 (3) 926-7687
or
United States
Denise Bradley, 215-591-8974

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:

The article Teva Files 2012 Annual Report on Form 20-F originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
…read more
Source: FULL ARTICLE at DailyFinance